(Q39773323)

14 September 2017

1 reference

title

Daunomycin: an anthracycline antibiotic effective in acute leukemia (English)

1 reference

14 September 2017

Daunomycin: An Anthracycline Antibiotic Effective in Acute Leukemia (English)

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

6 April 2023

1 reference

D. D. Von Hoff

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A358802

6 April 2023

M. Rozencweig

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A358802

6 April 2023

M. Slavik

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A358802

6 April 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=358802

6 April 2023

publication date

1 January 1978

1 reference

Advances in pharmacology and chemotherapy

14 September 2017

published in

1 reference

14 September 2017

volume

15

1 reference

14 September 2017

page(s)

1-50

1 reference

Total synthesis of the antitumor antibiotic daunorubicin. Coupling of the sugar and aglycone

14 September 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

The pharmacokinetics of daunomycin in man

6 April 2023

2

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Daunomycin. I. The Structure of Daunomycinone

6 April 2023

4

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Journal of Pharmacology and Experimental Therapeutics

6 April 2023

7

182

63

Asbell

1972

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Journal of Pharmacology and Experimental Therapeutics

6 April 2023

8

177

573

Bachur

1971

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Journal of Pharmacology and Experimental Therapeutics

6 April 2023

9

175

331

Bachur

1970

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Journal of Pharmacology and Experimental Therapeutics

6 April 2023

10

177

567

Bachur

1971

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Journal of Pharmacology and Experimental Therapeutics

6 April 2023

11

191

331

Bachur Hildebrand

1974

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Plasma adriamycin and daunorubicin levels by fluorescence and radioimmunoassay

6 April 2023

12

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Daunomycin–Preliminary Results of the Treatment of Acute Leukemias in Adults

6 April 2023

14

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

6 April 2023

16

27

2565

Bernard

1967

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Daunorubicin therapy in adult acute lymphatic leukemia

6 April 2023

21

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Daunorubicin-Prednisone Treatment of Erythroleukemia

6 April 2023

22

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Therapy of adult acute leukemia with daunorubicin and L-asparaginase

6 April 2023

23

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Daunorubicin in the treatment of acute myelocytic leukaemia

6 April 2023

24

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Cardiac toxicity of daunorubicin

6 April 2023

25

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Treatment of acute myeloid leukaemia with cytosine arabinoside and daunomycin in combination

6 April 2023

26

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Treatment of therapy-resistant acute myeloid leukaemia with 7 and 8 cytostatics

6 April 2023

27

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Journal of Pharmacology and Experimental Therapeutics

6 April 2023

28

182

70

Bullock

1972

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

ON PHYSICO-CHEMICAL INTERACTIONS BETWEEN DAUNOMYCIN AND NUCLEIC ACIDS

6 April 2023

30

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Enhancement of rat liver uridine kinase activity by various metabolic inhibitors

6 April 2023

32

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Combination Chemotherapy using L-Asparaginase, Daunorubicin, and Cytosine Arabinoside in Adults with Acute Myelogenous Leukaemia

6 April 2023

33

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Management of adult acute myelogenous leukaemia.

6 April 2023

34

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

6 April 2023

35

32

1307

Dano

1972

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

‘Daunomycin’, a New Antibiotic of the Rhodomycin Group

6 April 2023

39

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Inhibiting effect of the new cytotoxic antibiotic daunomycin on nucleic acids and mitotic activity of HeLa cells

6 April 2023

41

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

[ELECTRON MICROSCOPE STUDY OF THE CHANGES PRODUCED BY DAUNOMYCIN IN HELA CELLS].

6 April 2023

44

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

6 April 2023

46

34

293

Edelstein

1974

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

6 April 2023

47

34

2243

Egorin

1974

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Sequential therapy for induction and maintenance of remission in acute myeloblastic leukemia

6 April 2023

48

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Management of acute non-lymphocytic leukaemia

6 April 2023

51

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Active immunotherapy used alone for maintenance of patients with acute myeloid leukaemia.

6 April 2023

55

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

The treatment of acute myeloid leukaemia

6 April 2023

56

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Combined Chemotherapy of Acute Myeloblastic Leukemia

6 April 2023

58

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Immunosuppressive activity of some new cytostatic agents

6 April 2023

59

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

The cardiotoxicity of adriamycin and daunomycin in children

6 April 2023

60

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Combination chemotherapy with cytosine arabinoside and rubidomycin in 30 cases of acute granulocytic leukemia

6 April 2023

61

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Effects of anticancer agents on the respiration of isolated mitochondria and tumor cells

6 April 2023

62

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

High-dose daunorubicin therapy for acute nonlymphocytic leukemia: correlation of response and toxicity with pharmacokinetics and intracellular daunorubicin reductase activity.

6 April 2023

63

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Intensive chemotherapy in children with acute lymphoblastic leukemia (L-2 protocol)

6 April 2023

65

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Daunorubicin cardiac toxicity in children with acute lymphocytic leukemia

6 April 2023

66

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Comparative cardiac toxicity of daunomycin in three rodent species.

6 April 2023

67

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Chemotherapy of acute lymphocytic leukemia of childhood

6 April 2023

68

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Clinical study of daunomycin (NSC-82151) in children with acute leukemia

6 April 2023

70

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Clinical Study of Daunomycin and Prednisone for Induction of Remission in Children with Advanced Leukemia

6 April 2023

71

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

6 April 2023

74

32

600

Huffman

1972

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Rubidomycin. A new agent active in the treatment of acute lymphoblastic leukaemia

6 April 2023

77

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

6 April 2023

78

33

3278

Jacquillat

1973

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

6 April 2023

81

31

84

Jones

1971

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Preliminary clinical screening with daunorubicin in lung cancer

6 April 2023

83

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

6 April 2023

84

28

2437

Kim

1968

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

The effect of cancer chemotherapeutic agents on fibrin formation and stabilization in vitro

6 April 2023

87

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

6 April 2023

90

34

2624

Lee

1974

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Impulsecytophotometric studies on the effects of daunomycin on synchronised L-cells

6 April 2023

91

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Rubidomycin in Acute Leukaemia in Adults

6 April 2023

94

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Daunorubicin in acute myelocytic leukaemia

6 April 2023

95

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

A second comparative trial of remission induction (by cytosine arabinoside given every 12 hours, or C.A.R. and thioguanine, or C.A.R. and daunorubicine) and maintenance therapy (by C.A.R. or methylgag) in acute myeloid leukaemia

6 April 2023

96

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Acute lymphoblastic leukaemia treated with a combination of prednisone, vincristine, and rubidomycin. Value of pathogen-free rooms

6 April 2023

100

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

6 April 2023

101

12

243

Mhatre

1970

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Induction and maintenance of remission in acute leukemia. Effectiveness of combination therapy in 227 patients

6 April 2023

107

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Influence of Chemotherapeutic Agents on the Antibacterial Activity of Normal and Leukemic Sera2

6 April 2023

108

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Daunomycin cardiac toxicity

6 April 2023

110

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

6 April 2023

111

31

409

Riehm

1971

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

6 April 2023

112

32

1195

Riehm

1972

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

The treatment of acute granulocytic leukemia in adults

6 April 2023

113

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

[ACTION OF DAUNOMYCIN ON NUCLEIC ACID SYNTHESIS IN HEPATOMA CELLS]

6 April 2023

114

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Daunorubicin therapy in advanced neuroblastoma

6 April 2023

116

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

6 April 2023

120

30

966

Silvestrini

1970

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

6 April 2023

121

26

2316

Simard

1966

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Journal of Pharmacology and Experimental Therapeutics

6 April 2023

127

195

41

Takanashi

1975

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia

6 April 2023

129

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Immunological relationship of DNA polymerase from human acute leukaemia cells and primate and mouse leukaemia virus reverse transcriptase

6 April 2023

130

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

The Kitasato archives of experimental medicine

6 April 2023

131

45

181

Umezawa

1972

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

6 April 2023

132

34

2546

VanVunakis

1974

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Vincristine, prednisone, and daunomycin in acute leukemia of childhood

6 April 2023

135

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases

6 April 2023

138

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Base Specificity in the Interaction of Polynucleotides with Antibiotic Drugs

6 April 2023

141

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

6 April 2023

142

33

921

Weil

1973

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

6 April 2023

Cancer Treatment Reports

143

60

1667

Weiss

1976

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

6 April 2023

145

32

2023

Wiernik

1972

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

6 April 2023

149

32

1177

Yesair

1972

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

Common Receptor-Complement Feature Among Some Antileukemic Compounds

6 April 2023

150

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

The inhibition of RNA polymerase by daunomycin

6 April 2023

151

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

The inhibition in vitro of DNA polymerase and RNA polymerases by daunomycin and adriamycin

6 April 2023

152

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

6 April 2023

153

35

754

Zunino

1975

1 reference

https://api.crossref.org/works/10.1016/S1054-3589(08)60480-9

6 April 2023

Identifiers

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=358802

6 April 2023

1 reference